- Home
- AG vs MDGL Comparison
AG vs MDGL Comparison
Compare AG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | MDGL |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 12.1B |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AG | MDGL |
|---|---|---|
| Price | $18.94 | $515.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $21.92 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 13.3M | 277.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $24.41 | $58.39 |
| Revenue Next Year | $10.68 | $48.55 |
| P/E Ratio | $143.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $265.00 |
| 52 Week High | $32.00 | $615.00 |
Technical Indicators
Market Signals| Indicator | AG | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 53.05 |
| Support Level | $17.88 | $503.93 |
| Resistance Level | $23.06 | $539.17 |
| Average True Range (ATR) | 0.85 | 16.12 |
| MACD | -0.08 | -3.62 |
| Stochastic Oscillator | 4.16 | 37.60 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.